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Objective: Radial arteries are increasingly used as conduits for coronary artery
bypass grafts, but perioperative graft vasospasm continues to be a concern. Phe-
noxybenzamine, verapamil/nitroglycerin solution, and papaverine have been advo-
cated as topical antispasmodic agents. We compared the relative efficacies and
durations of action of these agents.
Methods: Isometric tension developed in response to clinically important vasocon-
strictors was measured in 100 radial artery rings (from patients undergoing coronary
artery bypass grafting, n  25) after 15 minutes of ex vivo incubation with
phenoxybenzamine, verapamil/nitroglycerin solution, papaverine, or vehicle (con-
trol). Duration of action was assessed by measuring responses to vasoconstrictors in
antispasmodic pretreated and control rings at intervals through 5 hours.
Results: Verapamil/nitroglycerin solution reduced vasoconstriction in response to
epinephrine, angiotensin II, prostaglandin F2, and phenylephrine but its effect had
almost completely waned after 5 hours. Phenoxybenzamine prevented vasoconstric-
tion in response to epinephrine, dopamine, and phenylephrine, with its effect lasting
at least 5 hours. Papaverine had limited antispasmodic efficacy and prevented
vasoconstriction in response to potassium (60 mmol/L) and phenylephrine for only
1 hour at the longest.
Conclusions: Verapamil/nitroglycerin solution has a broad efficacy against a range
of vasoconstrictors but a limited duration of action. Papaverine has the shortest
duration of action. Phenoxybenzamine is an effective agent with a prolonged
duration of action, specifically preventing catecholamine mediated vasospasm of
radial artery conduits.
The increasing use of multiple arterial conduits in coronary arterybypass grafting (CABG) has followed the superior results initiallyachieved with a single internal thoracic artery (ITA)1 and morerecently with bilateral ITAs.2,3 Most patients undergoing CABGneed three or more grafts, and the radial artery has become theconduit of choice for the third graft.4 First used as an aorta-coronary
graft in 1971,5 it was subsequently abandoned because of high rates (35%) of
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postoperative narrowing or occlusion on angiography. In-
terest in the radial artery has been rekindled6 because it can
be harvested easily and safely, reaches any coronary target
comfortably, and can be used as either free or composite
grafts.4 Five-year patency rates between 85%7 and 92%8
have been reported. Despite its attractive handling charac-
teristics and improvements in harvesting technique, how-
ever, perioperative graft vasospasm continues to be a major
concern.6
The radial artery is a thick-walled, predominantly mus-
cular artery with a mean medial width of 500 m, compared
with 300 m for the more elastic ITA.9 The radial artery has
a greater contractility than the ITA,10 but the value appears
to be equivalent to that of the ITA when corrected for vessel
diameter. Ex vivo studies have demonstrated that sub-
stances such as endothelin I, angiotensin II,11 norepineph-
rine, serotonin, and thromboxane A2 cause greater vasocon-
striction in the radial artery than the ITA,12 suggesting that
the propensity toward spasm is not solely a function of the
muscular wall but that an enhanced reactivity to vasoactive
mediators is of key importance.11 The circulating levels of
many of these substances are increased during and after
cardiac surgery.13 In arterial conduits the predominant re-
ceptors responsible for these effects are -adrenergic,
thromboxane-prostanoid, and endothelin (types A and B)
receptors.14
Several topical and systemic pharmacologic preparations
have been used to reduce radial artery graft vasospasm.
Ideally, antispasmodic preparations should prevent vaso-
constriction in response to relevant contractile stimuli for a
prolonged period (throughout the postoperative period)
without damaging the conduit and while avoiding systemic
hemodynamic effects. Topical agents are especially attrac-
tive because they are easily administered during surgery and
do not have systemic hemodynamic effects. Because re-
peated application is not possible after chest closure, dura-
tion of action is of particular importance. Papaverine,15
verapamil/nitroglycerin solution (VG solution),16 and phe-
noxybenzamine are in clinical use as topical radial artery
antispasmodic agents. However, the relative merits and
weaknesses of these preparations in modulating radial artery
graft vasospasm are poorly defined. We therefore system-
atically compared these agents by examining their effects on
a range of contractile stimuli in human radial artery and
their durations of action.
Methods
Patients and Vessel Preparation
Ethical approval was given by the local research ethics committee
(OxREC C01.207). Radial artery specimens were obtained after
written informed consent from patients (n  25) undergoing total
arterial CABG. Patient demographic characteristics, numbers un-
dergoing urgent surgery, risk factors for atherosclerosis, and pre-
operative medications are shown in Table 1. The radial artery was
harvested with accompanying venae comitantes and connective
tissue intact, and a 1.5- to 2-cm segment was obtained from the
distal end and placed immediately in cold (4°C) Krebs-Henseleit
buffer solution (KHB; 120-mmol/L sodium chloride, 4.7-mmol/L
potassium chloride, 1.2-mmol/L magnesium sulfate, 1.2-mmol/L
potassium phosphate, 2.5-mmol/L calcium chloride, 25-mmol/L
sodium hydrogen carbonate, 5.5-mmol/L glucose). The arterial
segment was carefully dissected free of its adnexae and cut into
four vascular rings, each measuring 3 mm in length.
Vasomotor Studies
Isometric tension studies were performed by mounting vascular
rings on stainless steel hooks in 25-mL organ chambers containing
warm (37°C) KHB, constantly aerated with 95% oxygen and 5%
carbon dioxide. After 30 minutes of equilibration, all rings under-
went incremental passive stretching to achieve a steady resting
tension of 3 g. All contractile responses were measured from rings
at 3-g steady resting tension, which had been determined as opti-
mal in preliminary experiments. All experiments were conducted
in the presence of 10-mol/L indomethacin (Sigma, St Louis, Mo)
to inhibit prostanoid synthesis.
The maximum developed tension in response to the addition of
warm (37°C), aerated (95% oxygen and 5% carbon dioxide) mod-
ified KHB containing 60-mmol/L potassium ion (64.7-mmol/L
sodium chloride, 58.8-mmol/L potassium chloride, 1.2-mmol/L
magnesium sulfate, 1.2-mmol/L potassium phosphate, 2.5-mmol/L
calcium chloride, 25-mmol/L sodium hydrogen carbonate, 5.5-
mmol/L glucose) was measured in each ring. Each ring was then
incubated for 15 minutes with either phenoxybenzamine (10
mol/L; Goldshield Pharmaceuticals Ltd, Croydon, United King-
dom), VG solution consisting of a verapamil (Knoll Pharmaceu-
ticals, Mount Olive, NJ) and nitroglycerin (Schwarz Pharma, Mon-
heim, Germany) mixture (30 mol/L each16), or papaverine (266
mol/L or 0.1 mg/mL, Sigma). The remaining ring was left
untreated as a control.
The rings were washed after 15 minutes to remove excess
antispasmodic agent from the organ chambers. After 10 minutes of
equilibration, the response to modified KHB (60-mmol/L potas-
sium ion) was measured again. Cumulative dose responses to
TABLE 1. Patient clinical characteristics
Age (y, mean  SEM) 62 2.0
Sex (male/female ratio) 21:4








Calcium-channel antagonist 13 (52%)
Nitrate 9 (36%)
Angiotensin-converting enzyme inhibitor* 9 (36%)
Lipid-lowering agent 24 (96%)
Potassium-channel opener 3 (12%)
Diuretic 5 (20%)
*Includes patients receiving angiotensin II blockers.
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epinephrine (1-nmol/L to 10-mol/L; Sigma), angiotensin II (10-
pmol/L to 100-nmol/L; Sigma), phenylephrine (1-nmol/L to 10-
mol/L; Sigma), prostaglandin F2 (1-nmol/L to 10-mol/L;
Sigma), and dopamine (10-nmol/L to 100-mol/L; Martindale
Pharmaceuticals Ltd, Brentwood, United Kingdom) were then
measured serially in each ring.
Between successive vasoconstrictor applications, each ring was
washed twice with warm, aerated KHB, allowed to re-equilibrate,
and stretched passively to achieve a steady resting tension of 3g.
The time elapsed from treatment with antispasmodic agents was
noted for each vasoconstrictor addition in each ring. In subsequent
experiments, the order of addition of the five vasoconstrictors was
systematically rotated according to a cyclic scheme, enabling
measurement of the duration of action of each antispasmodic agent
versus each vasoconstrictor. Finally, the response to modified
KHB (60-mmol/L potassium ion) was measured. The protocol
is illustrated by raw data from a representative experiment
(Figure 1).
Statistical Analysis
Contractile responses were expressed as a percentage of the initial
response to modified KHB (60-mmol/L potassium ion) in individ-
ual rings. Data are shown as mean  SEM. Dose-response curves
were compared with control values by means of a general linear
model for repeated measures (SPSS for Windows 10.0; SPSS Inc,
Chicago, Ill). Two-tailed Student t tests were used to compare
receptor-independent responses and the maximal responses at each
time point with their respective control values.
Results
Efficacy of Antispasmodic Activity
To determine the relative efficacies of the antispasmodic
agents against a range of vasoconstrictors, radial artery rings
were incubated with either phenoxybenzamine, VG solu-
tion, papaverine, or vehicle (control) for 15 minutes. The
isometric tension developed in response to increasing con-
centrations of epinephrine, angiotensin II, phenylephrine,
prostaglandin F2, and dopamine was then measured seri-
ally in each ring (Figure 2). VG solution significantly re-
duced contractile responses to epinephrine, angiotensin II,
phenylephrine, and prostaglandin F2 but did not affect
contractions to dopamine. Incubation of vessel rings with
phenoxybenzamine prevented contractions to epinephrine,
dopamine, and phenylephrine but not prostaglandin F2;
contractile responses to angiotensin II were modestly aug-
mented at concentrations greater than 1 nmol/L. In contrast,
papaverine pretreatment resulted in no significant differ-
ences in contractile responses to any vasoconstrictor relative
to control rings. These findings suggest that phenoxyben-
zamine has a specific action against -adrenergic–mediated
radial artery constriction, whereas VG solution has activity
against a broader range of vasoconstrictive agents.
Duration of Antispasmodic Effect
Receptor-independent vasoconstriction. To investigate
the duration of activity of each antispasmodic agent, recep-
Figure 1. Representative data from 4 radial artery rings (n 1 patient) illustrating experimental protocol. Isometric
tension studies of vascular rings suspended in organ chambers. Rings were incubated for 15 minutes with
phenoxybenzamine, VG solution, papaverine, or vehicle (control, gray bar). Contractile responses (tension in
grams) to 60-mmol/L potassium ion (heavy arrows) and serial cumulative additions of dopamine, epinephrine,
angiotensin II, phenylephrine, and prostaglandin F2 (solid triangles) were measured while time elapsed from
initial exposure to antispasmodic agents was noted.
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tor-independent contractile responses to 60-mmol/L potas-
sium ion in antispasmodic-treated and -untreated (control)
rings were measured at two time points 5 hours apart
(Figure 3). VG solution virtually abolished the early con-
tractile response. Contractile activity had almost fully re-
turned by the late time point, showing that the effect of VG
solution was in large part lost after 5 hours. Similarly,
papaverine pretreated vessel rings contracted minimally in
response to 60-mmol/L potassium ion at the early time point
but exhibited a greater contractile response than control
preparations 5 hours later. Thus the antispasmodic effect of
papaverine failed to last 5 hours. Phenoxybenzamine incu-
Figure 2. Effects of antispasmodic pretreatment on receptor-mediated contractile response (n  25 patients).
Isometric tension studies of vascular rings incubated for 15 minutes with phenoxybenzamine (filled squares), VG
solution (open triangles), and papaverine (filled circles) were used to measure cumulative dose responses to
epinephrine (A), angiotensin II (B), phenylephrine (C), prostaglandin F2, and dopamine (E). Untreated rings were
controls (open diamonds). Data points represent mean  SEM contractile responses expressed relative to
response to 60-mmol/L potassium ion in individual rings before incubation with antispasmodic agents. For clarity,
dose responses to prostaglandin F2 and dopamine are shown on enlarged and reduced scales, respectively.
Asterisks indicate P < .05 versus controls.
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bation had no effect on potassium-mediated contraction at
either time point, providing further evidence for its speci-
ficity of action against the -adrenergic system.
Receptor-mediated vasoconstriction. Next, the dura-
tions of antispasmodic activity against specific receptor-
mediated vasoconstrictors were examined (Figure 4). We
measured the isometric tension developed by antispasmod-
ic-treated radial artery rings during a systematic protocol of
serial contractions with a rotating allocation of vasocon-
strictors, interspersed with a defined series of washes,
through a period of more than 5 hours. For analysis, con-
tractions to maximum concentrations of vasoconstrictors
were used and data were grouped into early (1.2  0.04
hours), mid (3.2  0.1 hours), and late (5.2  0.1 hours)
time points.
VG solution significantly attenuated the contractile re-
sponse to phenylephrine, prostaglandin F2, and angiotensin
II up to the early, mid, and late time points, respectively.
Contractility in response to dopamine was unaffected by
VG solution at any time. The late response to epinephrine
was reduced in VG solution–pretreated rings. Contractile
responses to most vasoconstrictors were greater at the late
time point in VG solution–treated rings, providing further
evidence for a loss in antispasmodic efficacy through a
5-hour period. Phenoxybenzamine abolished the contractile
responses to both epinephrine and phenylephrine up to the
late time point. A similar pattern was seen in those rings
exposed to dopamine, but only the response at the early time
point reached statistical significance. In contrast, responses
to angiotensin II and prostaglandin F2 were not altered by
phenoxybenzamine treatment at any time point. Papaverine
treatment reduced the contractile response to phenylephrine
at the early time point but had no significant effect against
any other agonist at any other time point.
Discussion
The most important findings in this study were as follows:
1. VG solution prevented vasoconstriction mediated by
most of the contractile agonists used but was ineffec-
tive after 5 hours.
2. Phenoxybenzamine was highly effective in preventing
-adrenergic–mediated vasoconstriction for at least 5
hours, but this action was specific and did not extend
to other vasoactive mediators.
3. The antispasmodic effect of papaverine was limited to
approximately 1 hour duration only.
Strengths
Major strengths of this work include the direct comparison
of three currently used topical antispasmodic agents in 100
radial artery rings from 25 patients undergoing CABG. This
is the largest systematic study of this kind to date.
Second, we chose to study a range of vasoconstrictors
with direct clinical importance. Cardiopulmonary bypass
and surgical stress cause immediate 20-fold elevations in
plasma levels of epinephrine, to concentrations similar to
those used in this study, and elevations remain until at least
a day after surgery.17 Epinephrine infusions are used in the
management of low cardiac output states, further increasing
the circulating levels of this vasoconstrictor. Similarly, an-
giotensin II levels after cardiopulmonary bypass have been
measured at 0.2 nmol/L.18 Plasma levels of dopamine are
not consistently elevated after cardiopulmonary bypass, but
the agent may be administered intravenously as a pressor
after cardiac surgery.13 Prostaglandin F2 is a potent vaso-
constrictor of arterial conduits.14
Interpretation
VG solution, a mixture of verapamil (a highly selective
voltage-dependent calcium-channel antagonist with a
plasma half-life of up to 4.8 hours19) and nitroglycerin (a
nitric oxide donor with a short half-life) was first suggested
by He and colleagues20,21 for saphenous vein and ITA
conduit preparation. The same authors subsequently dem-
onstrated vasodilatation in response to VG solution applied
to radial artery rings precontracted with potassium chlo-
ride16 and reported that the effect persisted for at least 24
hours in radial artery segments stored for 24 hours at 4°C.
Whereas our study confirms that VG solution virtually
eliminates receptor independent vasoconstriction 30 min-
utes after incubation and is also effective against adrenergic,
thromboxane, prostanoid, and angiotensin mediated vaso-
Figure 3. Durations of antispasmodic effects against receptor-
independent vasoconstriction. Isometric tension studies of radial
artery rings (n  22 patients) incubated for 15 minutes with
phenoxybenzamine (PXB), VG solution (VG), or papaverine (Pap).
Control rings were incubated with vehicle only. Contractile re-
sponses to 60-mmol/L potassium ion were then measured at early
(filled bars, 0.52  0.02 hours) and late (open bars, 5.64  0.14
hours) time points. Bars represent mean  SEM contractile
responses expressed relative to response to 60-mmol/L potassium
ion in individual rings before incubation with antispasmodic
agents. Asterisks indicate P < .05 versus responses at early time
points.
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constriction, we found that the effect was largely lost within
5 hours. Certain aspects of our experimental protocol may
explain the difference in the durations of action reported by
ourselves and by He and colleagues.16 First, our radial
artery segments were exposed to the antispasmodic agents
for 15 minutes, rather than the 45 minutes recommended by
He and colleagues,16 because longer exposure is often im-
practical in the operating room. Second, the storage of VG
solution–treated rings for 24 hours at 4°C does not reflect
the clinical situation.
In recent years there has been considerable interest in the
use of phenoxybenzamine as a topical antispasmodic for
radial artery conduit preparation. It is a nonselective -ad-
renoceptor antagonist, with a long duration of action result-
ing from alkylation of the target receptors. Our group ini-
tially reported the efficacy of phenoxybenzamine versus
epinephrine-mediated vasoconstriction in the radial artery22
and noted that it does not cause endothelial dysfunction.23
Its efficacy in preventing norepinephrine-mediated vasocon-
striction has been clearly demonstrated.24 Recent contribu-
Figure 4. Durations of antispasmodic effects against receptor-mediated vasoconstriction. Isometric tension stud-
ies of radial artery rings incubated for 15 minutes with phenoxybenzamine (PXB), VG solution (VG), or papaverine
(PAP). Control rings were incubated with vehicle only. Bars represent mean  SEM contractile responses to
10-mmol/L epinephrine (A), 100-mmol/L angiotensin II (B), 10-mmol/L phenylephrine (C), 10-mmol/L prostaglandin
F2 (D), and 100-mmol/L dopamine (E) in control (untreated) and antispasmodic-pretreated vascular rings. Con-
tractile responses (expressed relative to response to 60-mmol/L potassium ion in individual rings before incubation
with antispasmodic agents) were measured at 1.2  0.04 hours (EARLY, white bars), 3.2  0.1 hours (MID, shaded
bars), and 5.2  0.1 hours (LATE, black bars) after antispasmodic pretreatment. For clarity, responses to
prostaglandin F2 and dopamine are shown on enlarged and reduced scales, respectively. At each time point 3 to
5 vascular rings were measured. Asterisks indicate P < .05 versus time-matched controls.
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tions to the literature suggest reductions in dose and treat-
ment time and have found the ex vivo durations of action of
phenoxybenzamine in preventing catecholamine-mediated
vasoconstriction to be variously 18 hours24 and 48 hours.25
This study used a low dose (10 mol/L) and a clinically
relevant treatment time (15 minutes) to confirm that phe-
noxybenzamine abolishes -adrenoceptor–mediated vaso-
constriction in human radial artery for at least 5 hours. To
achieve these effects in the clinical setting, we recommend
the immersion of the harvested radial artery in 100 mL
heparinized blood containing 4 mg phenoxybenzamine.
In addition, this study extends the physiologic under-
standing of the action of dopamine in phenoxybenzamine
pretreated radial artery conduits, with vasorelaxation ob-
served in response to dopamine concentrations of 1 mol/L
and above. In the peripheral vasculature the effects of do-
pamine are mediated by D1 and -adrenoceptors, with re-
sultant vasodilatation and vasoconstriction, respectively.26
Blockade of -adrenoceptors may unmask its D1-mediated
effects. Although the contractile response to dopamine was
small compared with those of other agonists, this may
contribute to the pathogenesis of vasospasm in arterial con-
duits. The ability to prevent dopamine-mediated vasocon-
striction increases the safety of using radial artery conduits
in CABG.
The second novel finding is the increased contractility in
response to angiotensin II in phenoxybenzamine pretreated
radial arteries. Angiotensin II is a potent vasoconstrictor at
low concentrations, and its effects are mediated by the
G-protein–linked AT1 receptor.27 -Adrenoceptors are also
G-protein coupled and may share components of intracel-
lular signaling cascades with AT1 receptors.28 Interactions
between 1-adrenoceptors and AT1 receptors have been
demonstrated in rat vascular smooth muscle cells,29 and
blockade of -adrenoceptors may enhance the contractile
response to angiotensin II. It is postulated that receptor
recycling results in up-regulation of angiotensin receptors or
prevents direct cross talk between AT1 receptors and -ad-
renoceptors. Although phenoxybenzamine is highly specific
for its target receptors, the downstream effects of receptor
blockade may be more widespread. Ultimately, phenoxy-
benzamine pretreatment may contribute to vasospasm if this
is mediated predominantly by noncatecholamine factors.
Papaverine, a phosphodiesterase inhibitor with a half-life
of 100 minutes, is widely used during ITA harvesting to
reverse spasm resulting from surgical manipulation. Gentle
hydrostatic dilation with papaverine solution (1 mg/mL) has
been advocated for radial artery harvesting.15 Our previous
work demonstrated that incubation with this concentration
of papaverine caused endothelial dysfunction in harvested
radial artery.23 In this study we therefore used a dose (0.1
mg/mL) that was capable of preventing vasoconstriction
while maintaining acetylcholine-dependent endothelial
function. However, the limited durations of action against
both receptor-mediated and receptor-independent vasocon-
striction is insufficient to recommend the use of papaverine
as an effective topical antispasmodic preparation.
Limitations
The etiology of radial artery graft vasospasm is likely to be
multifactorial, resulting from a combination of surgical in-
jury during harvest, exposure to circulating vasoactive me-
diators, and preexisting endothelial and medial smooth mus-
cle dysfunction in those with vascular disease states such as
diabetes mellitus or hypercholesterolemia. The ex vivo iso-
metric tension model allows the study of vasomotor re-
sponses to individual vasoactive mediators in isolation and
does not model the complex interactions that may occur in
the postoperative patient. We limited the number of vaso-
constrictors used to those of clinical importance, fully
aware that the use of different agonists might have al-
lowed further characterization of antispasmodic activity
and mechanism.
A further limitation of this work is that contractile re-
sponses were measured only up to 5 hours after antispas-
modic treatment. However, it is clear from the data that the
antispasmodic effects of VG solution and papaverine had
subsided by this point, whereas the effects of phenoxyben-
zamine were maintained. In addition, the effect of a contin-
uous circulation eluting topically administered antispas-
modic agents from conduits was only crudely modeled in
these experiments. In this respect an in vivo model may be
more helpful in determining the true durations of action of
these agents.
Conclusion
This study shows that no single topical antispasmodic agent
currently fulfills all the criteria necessary to prevent radial
artery vasospasm in clinical practice. VG solution is effec-
tive against a broad range of vasoconstrictors, but its rela-
tively short duration of action limits its usefulness in the
clinical setting. Phenoxybenzamine is a more effective
agent to prevent -adrenergic spasm than VG solution or
papaverine. Its prolonged duration of action makes it a
useful agent in the immediate postoperative period after
CABG, especially in patients requiring inotropic support
with epinephrine, norepinephrine, or dopamine. However,
phenoxybenzamine has little effect on vasoconstriction
caused by most other vasoactive mediators. Papaverine,
with the shortest duration of action and limited efficacy
against relevant vasoconstrictors, is not a useful topical
antispasmodic for radial artery conduits. A combination of
agents may be more appropriate to combat vasospasm and
thereby reduce the likelihood of early graft failure.
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